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Central message (174/200 characters + spaces): 
 
Fontan repair is palliative. With increasing late survival, we must now learn how to 
manage our success. Late Fontan problems are intractable. New therapies can prevent 
them.  
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 This article reminds us of the fate of the Fontan patient, and our obligation to 
provide the best possible care over their lifetime [1]. It outlines the potential benefits of 
improving, in so far as possible, the known factors that adversely affect hemodynamics. 
Efforts to reduce these risk factors should be pursued when reasonable to do so. The risks 
of multiple reoperations will, however, need to be balanced against the potential, but as 
yet unproven, benefits. 
 
 At the same time, the article reminds us that Fontan repair is palliative [2-4]. After 
5 decades, the long-term fate of the Fontan circulation is now clearly framed as an 
intractable problem that culminates in a host of secondary diseases [5]. After all, the 
absence of a subpulmonary ventricle is physiologically profound. Medical therapies do 
not provide clear solutions. Late surgical optimization of correctible factors is important, 
but cannot overcome the non-correctible factors. 
 
 Mechanical circulatory support (MCS) has, up to now, generally focused on the 
application of systemic support in end-stage Fontan disease using existing devices. 
However, this is highly problematic. Existing MCS technology is better suited to 
ventricular failure in Fontan, rather than Fontan failure secondary to lack of a 
subpulmonary ventricle. In the setting of preserved systolic function (>70% at late 
follow-up [6]), systemic MCS is superfluous; in fact, it may further congest the right-
sided circulation where the circulatory bottleneck exists, and exacerbate Fontan disease. 
Transplantation is not a comprehensive solution, and represents end-stage therapy. 
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Current therapies are incremental and aimed at optimizing palliation; they are not capable 
of resolving the underlying physiologic deficit (i.e. cure). So, where do we go from here? 
 
 A fundamentally different approach is possible with curative potential for our 
single ventricle patients. Biventricular equivalency can be maintained in the single 
ventricle circulation with the use of cavopulmonary assist, preempting Fontan disease [7]. 
A highly specialized, relatively innocuous, low-pressure (~6 mmHg) cavopulmonary 
assist device will reverse the Fontan paradox by reducing systemic venous pressure (~6 
mmHg) and improving preload (~2 mmHg), thereby improving cardiac output. A durable 
subpulmonary power source will permanently normalize the circulation. 
 
 Rather than applying MCS for end-stage salvage, we need to apply it 
preemptively for biventricular health maintenance. Rather than Fontan perpetuation, we 
need Fontan reversal. 
 
 To paraphrase the venerable words of John F Kennedy, I believe that this [field] 
should commit itself to achieving the goal, within a decade, of [reversing the Fontan and 
emulating biventricular circulatory health in single ventricle patients]. A Fontan-specific 
device is necessary; existing technology will not scale [8]. Devices that can safely and 
reliably achieve this vision are in development and within reach. 
 
 The treatment of single functional ventricle has not significantly changed for 
decades, succeeding only in prolonging an inherently inefficient system. To change long-
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term outcomes, it is time to replace what is missing. We can solve the unimaginable and 
shift the paradigm for single ventricle care to one based on biventricular health. Our 
single ventricle patients stand to benefit greatly. 
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